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Abstract
Background: The Disease Burden Morbidity Assessment (DBMA) is a self-report questionnaire used to estimate the
disease burden experienced by patients. The aim of this study was to test and to measure the properties of the
French translation of the DBMA (DBMA-Fv).
Methods: The original version of the DBMA was translated into French (Canadian) and first assessed during
cognitive interviews. In the validation study, patients recruited during consecutive consultation periods completed
the DBMA-Fv questionnaire while they were in the waiting room of a primary care setting (T1). Participants
completed the same questionnaire mailed to their home two weeks later (T2). Concomitant validity of the DBMA-
Fv was assessed using the Cumulative Illness Rating Scale (CIRS). Patient medical records were reviewed to verify
chronic diseases and past medical history.
Results: Ninety-seven patients were recruited and 85 (88%) returned the mailed questionnaires; 5 (5.9%) were
incomplete. DBMA-Fv scores of the 80 participants with a complete questionnaire at T2 ranged from 0 to 30
(median 5.5, mean 7.7, SD = 7.0). Test-retest reliability of the DBMA-Fv was high (ICC: 0.86, 95% CI: 0.79-0.92). The
DBMA-Fv and the CIRS correlated moderately at T1 (r = 0.46, 95% CI: 0.26 - 0.62, p < 0.01) and T2 (r = 0.56, 95% CI:
0.38 - 0.70, p < 0.01). The mean (SD) sensitivity of patient reports of a condition in relation to chart review at T2
was 73.9 (8.4) (range 62.5% to 90%). The overall mean (SD) specificity was 92.2 (6.7) (range 77.6% to 98.6%).
Conclusions: The DBMA-Fv’s properties are similar to its English counterpart as to its median sensitivity and
specificity compared to chart reviews. It correlated moderately with an established index of multimorbidity. A high
percentage of patients were able to complete the test correctly as a mail questionnaire and it showed high test-
retest reliability.
Background
Studies on multimorbidity should rely on valid and
robust measurement to assess the disease burden experi-
enced by patients with chronic diseases. Previous studies
have shown that a measure that includes a weighting for
severity is a better predictor of patient-related outcomes
than a measure based on a simple disease count [1,2].
Severity can be judged on purely clinical grounds by
health professionals or on the basis of the illness experi-
enced by patients themselves. However, impact on daily
living seems to be best evaluated by the patient because
self-reported disease burden correlates with quality of
life outcomes more strongly than measures of comor-
bidity based on other methods of data collection [3].
The Disease Burden Morbidity Assessment (DBMA) is a
self-report questionnaire that seems promising in this
respect [3]. There are many instruments designed to
measure multimorbidity, such as the Cumulative Illness
Rating Scale (CIRS) [4], the Charlson index [5], the
Index of Coexistent Disease [6], and the Shwartz index
[7]. However, these indexes have to be administered by
professionals because of the medical background
required to complete them. This is a limitation to using
these instruments in large samples of patients either in
primary care settings or the general population. The
DBMA does not have this limitation. The DBMA is
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easily completed by older people and original validity
assessment revealed good sensitivity and specificity
using the chronic disease list in the medical chart as a
gold standard [3,8]. Test-retest reliability and concomi-
tant validity of the instrument have not been reported
yet. The aim of this study was to test and to measure
the properties of the French translation of the DBMA
(DBMA-Fv). Specifically, we were interested in test-ret-
est reliability, concomitant validity with another measure
of multimorbidity and to explore the criterion diagnostic
validity (sensitivity/specificity) with a gold standard.
Methods
The instrument
The DBMA is a self-report questionnaire in which the
patient must rate a number of medical conditions, if
present. The original version of the DBMA included 23
common medical conditions [3]. The instrument was
later modified, and the number of conditions was
reduced to 21 [8]. The instrument used for this study
was the latter version with an additional item exploring
depression/anxiety. In the original article of Bayliss and
colleagues [3], depression was assessed as a separate
outcome measure but due to its importance in patients
with multimorbidity [9] we decided to include it as the
22nd item. For each condition present, the patient
assesses the degree to which the condition limits his/her
daily activities on a five-point descriptive scale in which
the first level, “not at all”, has a weight of 1, and the
fifth level, “a lot”, has a weight of 5; all other conditions
are scored zero. The questionnaire also allows patients
to add medical conditions not included in the list and
to score them in the same way. The total score is the
sum of the limitation from all conditions, including
those added by the patient. The questionnaire is written
in a simple language understandable to patients using
short sentences. The English version of the question-
naire is shown in more detail in an additional file (see
Additional file 1).
Translation
The original version of the DBMA [8] was translated in
French Canadian following a procedure inspired by Val-
lerand [10] and Hébert [11]. Although forward-back-
ward translation is a method commonly used for
translating questionnaires in the field of patient-reported
outcomes, given the simple nature of the questions we
estimated that this procedure was not necessary. A
bilingual translator translated the original version into
French. A panel of experts examined both versions and
made revisions to further adapt it to Quebec French.
The translated version (DBMA-Fv) was then submitted
to a panel of experts (three physicians and one nurse).
The panel verified that the disease list of the instrument
faithfully reflected the English version, and that the lan-
guage was well adapted to the one used by patients seen
in primary care. If any discrepancy was found, modifica-
tions and specifications were made to the questionnaire
following expert recommendations.
Cognitive interview
The DBMA-Fv was first assessed during cognitive inter-
views to make sure all items were clearly written, with-
out ambiguity, and in a language that could easily be
understood by the target population. To achieve this,
two of the authors (MF and CH) recruited a conveni-
ence sample, as recommended by Dillman [12], from
their consulting patients. The sample included 10
patients (7 women) aged from 19 to 79 years (mean ±
SD, 63.3 ± 16.9) suffering from various chronic diseases,
in a clinical practice. Patients agreeing to participate
provided written consent. At each interview, an observer
was also present. The interviewer and the observer were
research assistants trained by one of the authors of the
study (MEP). At the time of the interview, participants
were asked to read the questions of the DBMA-Fv out
loud and to express any thoughts or doubts they had, or
to highlight ambiguities they may find while answering
the questions. The interviewer led the activity while the
observer had the task to note all the questions and com-
ments of the participants. The maximum duration of
interviews was 30 minutes.
After each interview, the interviewer and the observer
met three authors of the study (MEP, MF and CH) in
order to discuss the comments expressed by the partici-
pant. Questions identified as unclear were clarified by
the research team for the next participant and so on
until no further change was required. The questionnaire,
modified according to participant input, was then con-
sidered to be in its final format and applied in the vali-
dation study. The final version of the DBMA-Fv
validated in this study is shown in more detail in an
additional file (see Additional file 2).
Validation study
The patients were recruited by a research assistant dur-
ing consecutive consultation periods from the waiting
room of the Family Medicine Unit (FMU) of a regional
health centre (Centre de santé et de services sociaux de
Chicoutimi) in Saguenay (Quebec) Canada. We aimed
to recruit a sample of 100 participants to test the instru-
ment [12]. Patients solicited were asked to provide writ-
ten consent and to complete a short questionnaire to
determine eligibility. Participants had to be at least 18
years old, patients at the FMU for more than two years
and able to read and write in French. Pregnant women,
patients with an unstable acute condition, or having an
uncontrolled psychiatric disease, a cognitive disorder, or
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unable to provide informed consent were not included
in the study. Eligible patients were asked to complete
the DBMA-Fv questionnaire without assistance while
they were in the waiting room of the FMU (T1). Filling
out the questionnaire took no more than 15 minutes.
Participants agreed to complete the same questionnaire
sent to their homes two weeks later (T2) and provided
consent to the research team to access their medical
records.
A second copy of the questionnaire along with a letter
inviting participants to answer was sent to those who
did not return the questionnaire one week after the date
of the first mailing. Participants who did not answer the
questionnaire one month after their recruitment were
called up by the research coordinator of the study to
point out the importance of their participation or to
accept their withdrawal from the study.
A trained research nurse reviewed the medical records
and completed a data extraction grid, including the list
of chronic diseases and past medical history of each par-
ticipant. This data was used to complete, first, a DBMA-
Fv based on chart review and also to score the CIRS,
another multimorbidity index [4], to assess concomitant
validity. The measurement properties of the CIRS and
the validity of this method for scoring the CIRS have
been described elsewhere [1,13,14]. Briefly, the CIRS
uses a scoring system that encompasses 14 anatomical
domains (cardiac, vascular, hematological, respiratory,
ophthalmologic-otorhinolaryngologic, upper gastroin-
testinal, lower gastrointestinal, hepatic-pancreatic, renal,
genitourinary, musculoskeletal-tegument, neurological,
endocrine-metabolic-breast, and psychiatric) and assigns
a value from 0 (no impairment of the organ or system)
to 4 (extremely severe impairment that is a life-threaten-
ing condition) to determine a severity score for each
domain. In the case of multiple conditions affecting a
particular domain, the condition with the highest score
determines the score given to the domain. The global
score is the sum of each domain’s score.
Data analysis
Missing data were analyzed by number of incomplete
questionnaires and by unanswered items in the ques-
tionnaire. Questionnaires with one missing value or
more were considered incomplete. To evaluate the test-
retest reliability, we calculated the intraclass correlation
coefficient (ICC) of the total score of the DBMA-Fv.
After checking for normality of the distributions, the
Pearson correlation was used to measure the concomi-
tant validity of the DBMA-Fv compared to the CIRS.
The 95% confidence interval (CI 95%) for the correlation
coefficient of the DBMA-Fv vs. CIRS relationship at T1
and T2 was calculated using Fisher’s Z transformation
[15]. Analyses of sensitivity and specificity with a 95%
CI were carried out for each medical condition included
in the DBMA-Fv when numbers were sufficient. The
‘gold standard’ used to calculate sensitivity and specifi-
city was the information contained in the medical
records. These analyses compared the questionnaires
completed by patients to those completed by the
research nurse using patient charts. Since the DBMA
was originally developed as a mail survey, we used the
results of the mail questionnaire at T2 to assess diag-
nostic validity. Conditions found in an insufficient num-
ber of subjects (five or less) to provide a good
estimation of the sensitivity were not included. Ill-
defined diagnoses (back pain, stomach problem, colon
problem, poor circulation) unlikely to be found in the
chart review were also excluded from the estimation of
sensitivity.
The SPSS 16.0 Software was used for data analysis.
Questionnaires with missing values were excluded from
analyses of test-retest reliability and concomitant valid-
ity. Approval for this project was obtained from the
ethics committee of the Centre de santé et de services
sociaux de Chicoutimi in February 2009.
Results
A total of 100 patients were invited to participate in the
validation study. Of those, 97 accepted and were eligible.
The majority of participants were women (Table 1). At
T1, nineteen patients (19.6%) did not answer some
items and the questionnaire was considered incomplete.
In total, 31 items were not answered and, among them,
in 19 cases the medical condition was not reported in
the chart either. Missing values did not cluster around
any one disease. At T2, the total of unanswered items
was only five (6%), i.e. one unanswered question in five
patients, and in two cases, the medical conditions were
not present in the chart. Significant differences between
patients who completed the questionnaire correctly and
those who did not were observed at T1 for age, CIRS
score, education and marital status (Table 1). However,
in a multivariate logistic regression model, age (p <
0.05) was the most important factor associated with an
incomplete questionnaire; sex (p = 0.37), education (p =
0.1), and CIRS score (p = 0.78) were not important.
Taking into account the DBMA-Fv responses at T2
(less unanswered items), the most frequent conditions
reported by the patients were elevated cholesterol
(32.9%), overweight (32.1%), stomach problem (30.6%),
hypertension (26.2%), and osteoarthritis (25.9%). The
conditions for which patients reported that the condi-
tion limited their daily activities “a lot” were other rheu-
matic diseases (14.3% of patients with the condition),
back pain (10% of patients with the condition), angina/
coronary artery disease (8.3% of patients with the condi-
tion), hard of hearing (7.1% of patients with the
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condition), and stomach problem (3.8% of patients with
the condition). Four patients added medical conditions
not included in the list: two patients added allergies, one
patient added Raynaud’s syndrome, and one patient
added tinnitus. These conditions were not considered in
the validation analyses.
Reliability
At T1, DBMA-Fv scores of the 78 participants who cor-
rectly completed the questionnaire ranged from 0 to 27
(median 5.0, mean 6.4, SD = 6.1). At T2, of the 97
mailed questionnaires, 85 (88%) were returned by the
patients. Among these, 5 (5.9%) were incomplete.
DBMA-Fv scores of the 80 participants with a complete
questionnaire at T2 ranged from 0 to 30 (median 5.5,
mean 7.7, SD = 7.0). Test-retest reliability of the
DBMA-Fv was high (ICC: 0.86, 95% CI: 0.79-0.92)
among the 66 questionnaires with complete responses at
T1 and T2.
Validity
Concomitant validity: Scores of the CIRS ranged from 0
to 19 (median 7, mean 7.1, SD 4.3). The DBMA-Fv and
the CIRS correlated moderately at T1 (r = 0.46, 95% CI:
0.26 - 0.62, p < 0.01) and T2 (r = 0.56, 95% CI: 0.38-
0.70, p < 0.01). We also calculated the concomitant
validity by considering only the questionnaires with
complete data at T1 and T2 and obtained similar results
(N = 66 (r = 0.45, 95% CI: 0.23 - 0.62, p < 0.01) and at
T2 (r = 0.54, 95% CI: 0.34 - 0.69, p < 0.01).
Diagnostic validity: Table 2 reports the sensitivity and
specificity measures at T2 calculated with the complete
questionnaires. The gold standard used was the diagno-
sis of the condition obtained from the chart review. The
mean ± SD sensitivity of patient reports of a condition
in relation to chart review at T2 was 73.9 ± 8.4 (range
62.5% to 90%). The overall mean ± SD specificity was
92.2 ± 6.7 (range 77.6% to 98.6%).
Discussion
The results of our study suggest that the DBMA-Fv pro-
vides a good estimate of the disease burden of patients
seen in primary care. The properties of the DBMA-Fv
are similar to its English counterpart as to its median
sensitivity and specificity compared to chart reviews,
and its correlation with a multimorbidity index which is
sensitive to quality of life outcomes. In addition, it has
good test-retest reliability. It accounts for many chronic
diseases commonly seen in primary care practice. Pre-
vious studies have shown associations between DBMA
score and quality of life, age, ‘compound effects of con-
ditions’ (treatments and symptoms interfering with each
other), self-efficacy (confidence in managing one’s medi-
cal conditions), financial constraints, and physical func-
tioning [3,8]. The DBMA-Fv provides an alternative for
multimorbidity measurement in studies based on a self-
report survey design.
Estimated for the first time, the test-retest reliability of
the DBMA-Fv was satisfactory and similar to previous
reports of comparable instruments [14,16].
The DBMA-Fv significantly correlated with the CIRS,
a well-validated index of multimorbidity. The correlation
was good but not perfect which is expected from instru-
ments based on different constructs. The CIRS was
Table 1 Characteristics of the Sample at T1




Mean (SD) age in years 47.4 (15.9) 57.6 (13.6) 0.01*
Male% 32.1 36.8 0.32†
Mean (SD) CIRS score 6.6 (4.0) 8.8 (5.4) 0.04*
Education% < 0.01†
< 8 y 5.1 10.5
8 to 12 y 24.4 47.4
> 12 y (college or university) 70.5 42.1
Household income in Canadian 0.95†
dollars,%
< $29,999 24.3 26.4
≥ $30,000 71.9 73.6
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designed to be completed during a clinical assessment,
all diseases are evaluated, and scorers are required to
have an appropriate background to complete the scale,
whereas the DBMA is a self-report measure of disease
burden.
Apart from the built-in evaluation of the impact on
daily living, the DBMA-Fv is pretty simple to use and
comparable to other questionnaires used in large popu-
lation surveys [17], but shorter and easier to adminis-
trate. It could be used as a simple count of chronic
conditions. Using the same list of conditions in different
studies would allow better comparisons between them.
The instrument can also be used as a count weighted
for its impact on daily living for each condition.
The ‘gold standard’ used is considered a good refer-
ence point. However, with this study we could only
explore the diagnostic validity of the DBMA as it did
not have the statistical power to produce accurate esti-
mates of sensitivity (true sick among those self-declared
as sick) mainly because of the low prevalence of many
conditions included in this questionnaire among the
subjects of our sample. This resulted in large confidence
intervals that precluded a reliable interpretation in many
instances [18]. However, specificities (true negatives
among those declaring not being sick) were more pre-
cise as there were higher numbers involved in the
count. Nevertheless, in this study, mean specificity was
higher (92.2%) than mean sensitivity (73.9%) which con-
curs with the report of the original version in which
sensitivities and specificities were also calculated in rela-
tion to chart review [3].
Finding a sensitivity that is lower than the specificity
suggests that patients under-reported conditions present
in the medical chart [3]. This under-reporting may
reflect a tendency to ignore diagnoses that are of less
importance to them or even denied [3,19,20].
In this study, almost 20% of the questionnaires were
incomplete at T1 (waiting room survey). Nonetheless,
missing values did not cluster around any one disease,
suggesting that overall the disease list was clearly under-
stood. Distractions in the waiting room may have
accounted for a higher rate of incomplete questionnaires
at T1. Significant differences were found between
patients who correctly completed the questionnaire and
those who did not. Age was the most important factor
in our analysis. As multimorbidity increases with age, it
can be thought that the effect of age is due to a more
demanding task when completing the DBMA in older
patients. However, multimorbidity measured with the
CIRS was not an important factor in the multivariate
logistic regression model. Nevertheless, the number of
incomplete questionnaires was reduced to 6% at T2
using the mail questionnaire. A mail questionnaire is
thus more appropriate for this instrument.
This study has limitations. Statistical power is the
most important. Generalizability may be limited by the
characteristics of the population studied, a relatively
small sample of patients consulting and composed pre-
dominantly of women. The small sample size in this
study was sufficient for a good estimation of reliability
and concomitant validity but resulted in a lack of preci-
sion for criterion validity and sensitivity in particular. In
addition, we assumed that the presence of a diagnosis in
patient charts was a ‘gold standard’ in the assessment of
sensitivity and specificity, and this may not always be
the case. Some medical conditions are more likely to be
recorded in the chart, mainly those for which medica-
tions are prescribed. However, charts may be less accu-
rate for recording conditions that patients are less likely
to seek medical help for from their family doctor (hear-
ing loss for example). For sensitivity, in most cases the
confidence interval is very wide due to the small num-
ber of observations. Indeed, there were only three dis-
eases (hypertension, elevated cholesterol and asthma) in
which the 95% CI did not include the value of 50% and
therefore, showed more precision. The test-retest relia-
bility was analyzed using the 66 questionnaires with
complete responses at T1 and T2 and this might be a
Table 2 Sensitivity and specificity of the DBMA-Fv in relation to chart review at T2
Disease TP + FN* TP Sensitivity % CI 95%* TN + FP* TN Specificity % CI 95% Prevalence % (n) †
Hypertension 26 20 77.0 56.4 - 91.0 57 55 96.5 87.9 - 99.6 31.3 (83)
Elevated cholesterol 32 26 81.2 63.6 - 92.8 52 50 96.2 86.8 - 99.5 38.1 (84)
Asthma 10 9 90.0 55.5 - 99.7 74 71 95.9 88.6 - 99.2 11.9 (84)
Diabetes 12 9 75.0 42.8 - 94.5 72 71 98.6 92.5 - 100 14.3 (84)
Osteoarthritis 21 14 66.7 43.0 - 85.4 63 55 87.3 76.5 - 94.4 25.0 (84)
Rheumatic disease, other 22 15 68.2 45.1 - 86.1 62 56 90.3 80.1 - 96.4 26.2 (84)
Overweight 16 12 75.0 47.6 - 92.7 67 52 77.6 65.8 - 86.9 19.3 (83)
Angina/coronary artery disease 16 10 62.5 35.4 - 84.8 67 65 97.0 89.6 - 99.6 19.3 (83)
Depression/Anxiety 13 9 69.2 38.6 - 90.9 71 64 90.1 80.7 - 95.9 15.5 (84)
* TP = True Positive; FN = False Negative; TN = True Negative; FP = False Positive; CI 95% = 95% Confidence Interval.
† Total n = 84 (one chart could not be retrieved). Differences between the total n and the actual n used in calculations in some diseases are due to incomplete
data in the questionnaires that were not considered in the calculation.
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select group within our sample. Also, the test-retest
reliability was assessed using a mixed-mode approach
(first test administered in the waiting room and the sec-
ond test at home) which may have negatively influenced
the results. Nevertheless, the ICC was high.
In conclusion, the French translation of the DBMA is
a self-report estimate of disease burden that a high per-
centage of patients were able to complete correctly as a
mail questionnaire. It can be used in studies involving
primary care settings or the general population. It has
high test-retest reliability and correlated moderately
with an established index of multimorbidity, the CIRS.
The DBMA-Fv showed an adequate diagnostic sensitiv-
ity, which needs to be further studied in a larger sample
of subjects, and a very good diagnostic specificity. The
instrument is a subjective multimorbidity measure that
incorporates disease severity and explores the interfer-
ence of medical conditions with patients’ daily activities.
Additional material
Additional file 1: English version of the DBMA.
Additional file 2: French version of the DBMA.
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